Edwards Lifesciences Responds to CMS’s Proposed TAVR National Coverage Determination

Edwards Lifesciences reported that on March 3, 2012, the company filed its official response to the Centers for Medicare & Medicaid Services on its Proposed National Coverage Determination for Transcatheter Aortic Valve Replacement.
Qmed